NCT06960395 2026-03-17
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
Phase 1 Recruiting
Vir Biotechnology, Inc.
Kumquat Biosciences Inc.
Kumquat Biosciences Inc.
The First Affiliated Hospital of Xinxiang Medical College
GeneSail Biotech (Shanghai) Co., Ltd.
University of Kansas Medical Center
Qilu Hospital of Shandong University
M.D. Anderson Cancer Center
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Heronova Pharmaceuticals
GrandPharma (China) Co., Ltd.
Novartis
Weill Medical College of Cornell University